论文部分内容阅读
Aim: The purpose of this study is to evaluate the synergic effect of HAD-B 1 (Panax Notoginseng Radix, Cordyceps militaris, Panax ginseng C.A Mey, and Boswellia carterii BIRD WOO) combined with Afatinib on EGFR-L858R/T790M double mutation H 1975 lung cancer cell proliferation and tumor growth in a xenograft model.Methods: We investigated the anti-cancer effects of the HAD-B 1 combined with Afatinib on H1975 lung cancer cells and solid tumor growth in nude mice beating a H1975 human lung cancer xenograft.To assess the molecular mechanism of the anti-cancer effects of HAD-B 1, a ProteoChip-based Forwarded Phase Antibody Array and western blots were employed to identify the differential expression of cell cycle proteins.Results:Our results showed that co-treatment with HAD-B1 and Afatinib inhibited the proliferation of H1975 cells in a dose-dependent manner.Caspase activity of co-treatment group significantly increased compared with that of the control group.Antibody microarray-based proteomic analysis and western blotting analysis demonstrated that the anti-proliferative effect of HAD-B 1 on H1975 cells was caused by down-regulation of pERK1/2 and up-regulation of p16 in the cells.In in vivo tumor growth assay in xenograft animal model of human H 1975 lung cancer cells, the mean tumor volume in the group co-treated with HAD-B 1 and Afatinib showed a greater reduction than those of the control groups.Conclusion: Our studies suggest that the combination of HAD-B1 and Afatinib may be a novel approach in treatment for NSCLC and thus offer a new target for chemotherapy.We are planning the phase Ha clinical trial based on these results.